📅 PUBMED DAILY TRIAGE — 2026-05-23

Window: 2026-05-22T09:00 UTC → 2026-05-23T09:00 UTC (CRDT) Topics scanned: 10 | Candidates evaluated: ~85 | Abstracts reviewed: 35 High priority: 5 | Standard: 10 | Low/archive: ~70 | Unsolicited finds: 0 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Early Cancer Detection (Liquid Biopsy)

TR-2026-05-23-001 / PMID 42172311 · Single-nucleotide variant profiling in liquid biopsy with RECO-Cas · 8/10 · 🔴 EARLY_CANCER_DETECTION

CRISPR-Cas12a assay achieves 0.01% VAF sensitivity with 90.48% sens / 100% spec for KRAS/EGFR/PIK3CA mutations in clinical plasma cfDNA — with a POC-compatible smartphone platform — substantially advancing accessible liquid biopsy. Science Advances.

Precision Oncology / Genomic Medicine

TR-2026-05-23-002 / PMID 42172559 · Clinicogenomic Landscape of MTAP-Deleted Thoracic Malignancies Across US and Japanese Nationwide Cohorts · 8/10 · 🟠 NOVEL_TREATMENT

First cross-national landscape (US n=11,091 + Japan n=4,851) confirms ~8–20% MTAP deletion in lung cancer with strong CDKN2A co-deletion and frequent actionable driver co-occurrence (EGFR/ALK/ERBB2) — directly enabling design of MTAP synthetic lethal combination strategies. JCO Precision Oncology.

Novel Therapeutics — CAR-T / Hematologic Malignancies

TR-2026-05-23-003 / PMID 42172553 · In vivo gene therapy with CAR-T cells · 7/10 → HIGH · 🟠 NOVEL_TREATMENT

Leading CAR-T researchers (Wagner, Elsallab, Maus; Baylor/MGH/Harvard) summarize first clinical proof-of-concept for in vivo CAR gene delivery — bypassing complex ex vivo manufacturing — potentially democratizing access to CAR-T therapy for hematologic malignancies. Blood.

Rare Diseases / Cardiovascular-Metabolic (Sickle Cell Disease)

TR-2026-05-23-004 / PMID 42172505 · Estimated Glomerular Filtration Rate Discordance and Cardiopulmonary Morbidity in Sickle Cell Disease · 8/10 · 🟡 UNDERSERVED_POPULATION

In n=1,099 adults (223 with SCD), cystatin-C vs. creatinine eGFR discordance is markedly amplified in SCD and strongly associated with heart failure (aOR 4.65) and pulmonary hypertension (aOR 2.70) — establishing a simple, readily calculable non-invasive biomarker for cardiopulmonary risk in this underserved Black patient population. Blood Advances.

Novel Therapeutics — Gynecologic Cancer

TR-2026-05-23-005 / PMID 42172495 · HICARi Phase II: ASP-1929 photo-immunotherapy for RT-refractory EGFR+ vulvar/vaginal/cervical cancers · 7/10 → HIGH · 🟠 NOVEL_TREATMENT

First ever Phase II trial of ASP-1929 photo-immunotherapy (the world's only approved photo-immunotherapy, Japan-licensed for head/neck) in RT-refractory gynecologic cancers with EGFR+ tumors — addressing a major unmet clinical need with an entirely novel mechanism (light-activated membrane disruption). J Gynecol Oncology.

🟢⚪ STANDARD (5–7) — Top by Topic

Hematologic Malignancies

• TR-2026-05-23-006 / 42172714 · AML fault tree analysis, BeatAML2 cohort n=805 · 7/10 · Diagnostics — Novel risk stratification combining RUNX1/TP53/platelets → extreme-risk constellations (32.6%) with HR 2.03. Curr Res Transl Med.
• TR-2026-05-23-007 / 42172280 · DA-EPOCH-R vs R-CHOP in high-Ki67 DLBCL, n=405, East Asia · 6/10 · Treatment Innovation — No PFS/OS benefit; toleration issues limit DA-EPOCH-R in East Asians; clinically valuable null result. PLoS One.
• TR-2026-05-23-012 / 42172116 · Hodgkin lymphoma Czech registry, n=2,371 (24 years) · 5/10 · Public Health — 10-year OS >90% for <60 years; poor outcomes in elderly support checkpoint inhibitor/BV integration. Klin Onkol.

AI/ML in Diagnostics and Imaging

• TR-2026-05-23-008 / 42172670 · DL cervical spinal cord compression, 94.67% accuracy vs 69–71% for surgeons · 7/10 · 🟢 NEAR_TERM_IMPLEMENTABLE — External validated, plain-radiograph-based model; applicable in resource-limited settings. J Neurosurg Spine.
• TR-2026-05-23-009 / 42172660 · 30-day readmission prediction from minimal EHR codes, n=50K · 6/10 · 🟢 NEAR_TERM_IMPLEMENTABLE — Limited 11-feature set retains predictive signal enabling earlier intervention. JMIR Form Res.
• TR-2026-05-23-014 / 42172695 · Physics-informed DynUNet brain mets segmentation, +10.1% TC Dice external validation · 5/10 · Diagnostics. Comput Methods Programs Biomed.

Precision Oncology / Genomic Medicine

• TR-2026-05-23-010 / 42172690 · NSCLC TP53/STK11/KEAP1 co-mutations, n=437 prospective multicenter NGS · 6/10 · 🟢 NEAR_TERM_IMPLEMENTABLE — 70.3% without actionable drivers have clinically relevant co-mutations affecting immunotherapy. Cancer Treat Res Commun.
• TR-2026-05-23-011 / 42172550 · Pediatric cancer genomic testing disparities, UCSF NCCR, n=758 · 6/10 · 🟡 UNDERSERVED_POPULATION — Rural, female, teen patients under-tested; policy implications. JCO Oncol Pract.

Early Cancer Detection

• TR-2026-05-23-013 / 42172175 · CTC capture platform bispecific antibodies, in vitro HER2+ cells · 5/10 · Early Detection. J Phys Chem B.

Aging / Longevity

• TR-2026-05-23-015 / 42172195 · Hippocampal stem cell potential for cognitive aging, perspective · 5/10 · Prevention. PLoS Biology.

💡 UNSOLICITED FINDS

None identified. Sentinel scan (435 results) overlapped with watchlist topics; no novel high-signal out-of-watchlist items above threshold.

📊 TODAY'S BREAKDOWN

By research category:

• Early Detection: 2 (1 HIGH, 1 STANDARD)
• Treatment Innovation: 5 (3 HIGH, 2 STANDARD)
• Diagnostics: 5 (0 HIGH, 5 STANDARD)
• Genomics/Precision Medicine: 2 (1 HIGH, 1 STANDARD)
• Public Health: 3 (0 HIGH, 3 STANDARD)
• Prevention: 1 (0 HIGH, 1 STANDARD)

By evidence maturity:

• Exploratory: 9
• Validated: 5
• Potentially Practice-Changing: 0 (none met criteria at triage stage)

By watchlist topic (reviewed / kept / highest score):

By source type: peer_reviewed 15 | preprint 0

Topics with zero 8+ articles this run:

• CBC/ML hematology (0 results — 5th+ consecutive zero)
• AI/ML in clinical diagnostics (7/10 best; no 8+)
• Hematologic malignancies (7/10 best via CAR-T review — elevated to HIGH by flag)
• Aging/longevity (5/10 best)

🔧 RUN NOTES

CBC/ML hematology — persistent zero (5th+ consecutive run): This topic has returned 0 results again. Recommend query reformulation: broaden from strict CBC/ML/hematology to (hematogram OR CBC OR "blood count" OR "cell morphology") AND (AI OR model OR algorithm OR prediction) for next run. May also be naturally low-volume on weekends.

Saturday indexing: May 23 is a Saturday; PubMed CRDT indexing is typically lower volume on weekends. Total hematologic malignancy raw results (47) somewhat below recent daily averages (typically 60–100). This is expected.

AI/ML diagnostics (topic 4) — 4th+ consecutive run without 8+: Despite 95 raw results, top candidates are mostly orthopedic/spine applications and general hospital prediction models. No pure diagnostics with score ≥8 today. Recommend adding: AND ("AUC" OR "sensitivity" OR "specificity" OR "diagnostic performance") to filter for reporting diagnostic accuracy studies.

Cardio-metabolic coverage: 62 raw results but top candidates reviewed skewed to exercise physiology and animal models. SCD eGFR finding (42172505) was the highest-value hit, appearing across multiple watchlist topics. GLP-1/SGLT2-specific results were not prominent in top-10 — may require a date-adjusted search.

Rare diseases (5 results): Low daily volume, as expected. PMID 42172505 (SCD) is the primary rare disease finding.

Rolling context (from state): CBC/ML hematology zero streak now 5+ runs. AI/ML diagnostics no-HIGH streak now 4+ runs. CBC/ML query reformulation flagged for next run.